Evolus (EOLS) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $7.10, -6.21% vs the prior close of $7.57.
- Volume 761.68K shares, 0.8x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
EOLS slides 6.2% to $7.10, a 1-month low. Closed at $7.10, -6.21% vs the prior close of $7.57. Day range $7.02–$7.61, opened at $7.61.
EOLS daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — EOLS slides 6.2% to $7.10, a 1-month low
- Closed at $7.10, -6.21% vs the prior close of $7.57. Day range $7.02–$7.61, opened at $7.61.
- Volume was 761.68K shares, 0.8x its 50-day average of 957.29K.
- Price is -12.6% vs its 50-day average ($8.12) and +14.8% vs its 200-day average ($6.19).
- 52-week range $3.86–$9.31; today's close sits at 59% of that range, 23.7% below the 52-week high.
Oct 15, 2026 — EOLS jumps 4.8% to $7.57
- Closed at $7.57, +4.85% vs the prior close of $7.22. Day range $7.22–$7.71, opened at $7.26.
- Volume was 901.50K shares, 0.9x its 50-day average of 962.47K.
- Price is -6.8% vs its 50-day average ($8.13) and +22.4% vs its 200-day average ($6.19).
- 52-week range $3.86–$9.31; today's close sits at 68% of that range, 18.7% below the 52-week high.
Oct 14, 2026 — EOLS slides 3.9% to $7.22
- Closed at $7.22, -3.86% vs the prior close of $7.51. Day range $7.20–$7.60, opened at $7.42.
- Volume was 1.01M shares, 1.1x its 50-day average of 955.68K.
- Price is -10.8% vs its 50-day average ($8.10) and +16.8% vs its 200-day average ($6.18).
- 52-week range $3.86–$9.31; today's close sits at 62% of that range, 22.4% below the 52-week high.
Oct 13, 2026 — EOLS slides 3.1% to $7.51
- Closed at $7.51, -3.10% vs the prior close of $7.75. Day range $7.48–$7.70, opened at $7.68.
- Volume was 654.40K shares, 0.7x its 50-day average of 954.33K.
- Price is -7.0% vs its 50-day average ($8.08) and +21.5% vs its 200-day average ($6.18).
- 52-week range $3.86–$9.31; today's close sits at 67% of that range, 19.3% below the 52-week high.
Oct 12, 2026 — EOLS ends flat (+0.3%) to $7.75
- Closed at $7.75, +0.26% vs the prior close of $7.73. Day range $7.67–$7.83, opened at $7.76.
- Volume was 1.00M shares, 1.1x its 50-day average of 946.47K.
- Price is -3.7% vs its 50-day average ($8.05) and +25.5% vs its 200-day average ($6.18).
- 52-week range $3.86–$9.31; today's close sits at 71% of that range, 16.8% below the 52-week high.
Oct 9, 2026 — EOLS dips 0.9% to $7.73
- Closed at $7.73, -0.90% vs the prior close of $7.80. Day range $7.61–$7.83, opened at $7.77.
- Volume was 430.10K shares, 0.5x its 50-day average of 946.35K — lighter than usual.
- Price is -3.5% vs its 50-day average ($8.01) and +25.3% vs its 200-day average ($6.17).
- 52-week range $3.86–$9.31; today's close sits at 71% of that range, 17.0% below the 52-week high.
Oct 8, 2026 — EOLS rises 0.8% to $7.80
- Closed at $7.80, +0.78% vs the prior close of $7.74. Day range $7.53–$7.80, opened at $7.68.
- Volume was 1.08M shares, 1.1x its 50-day average of 941.05K.
- Price is -2.2% vs its 50-day average ($7.97) and +26.5% vs its 200-day average ($6.17).
- 52-week range $3.86–$9.31; today's close sits at 72% of that range, 16.2% below the 52-week high.
Oct 7, 2026 — EOLS jumps 4.9% to $7.74
- Closed at $7.74, +4.88% vs the prior close of $7.38. Day range $7.33–$7.75, opened at $7.37.
- Volume was 595.10K shares, 0.6x its 50-day average of 941.14K.
- Price is -2.5% vs its 50-day average ($7.94) and +25.6% vs its 200-day average ($6.16).
- 52-week range $3.86–$9.31; today's close sits at 71% of that range, 16.9% below the 52-week high.
Oct 6, 2026 — EOLS dips 1.2% to $7.38
- Closed at $7.38, -1.20% vs the prior close of $7.47. Day range $7.16–$7.56, opened at $7.47.
- Volume was 663.90K shares, 0.7x its 50-day average of 940.86K.
- Price is -6.7% vs its 50-day average ($7.91) and +19.8% vs its 200-day average ($6.16).
- 52-week range $3.86–$9.31; today's close sits at 65% of that range, 20.7% below the 52-week high.
Oct 5, 2026 — EOLS jumps 4.6% to $7.47
- Closed at $7.47, +4.62% vs the prior close of $7.14. Day range $7.07–$7.52, opened at $7.07.
- Volume was 786.40K shares, 0.8x its 50-day average of 939.07K.
- Price is -5.3% vs its 50-day average ($7.88) and +21.3% vs its 200-day average ($6.16).
- 52-week range $3.86–$9.31; today's close sits at 66% of that range, 19.8% below the 52-week high.
Oct 2, 2026 — EOLS slides 7.2% to $7.14, a 1-month low on 2.3x normal volume
- Closed at $7.14, -7.15% vs the prior close of $7.69. Day range $6.91–$7.72, opened at $7.72.
- Volume was 2.07M shares, 2.3x its 50-day average of 911.51K — unusually heavy trading.
- Price is -9.1% vs its 50-day average ($7.85) and +15.9% vs its 200-day average ($6.16).
- 52-week range $3.86–$9.31; today's close sits at 60% of that range, 23.3% below the 52-week high.
EOLS latest news & SEC filings
Every SEC filing by or about EOLS in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Sep 4, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Moatazedi David sold 105,108 shares at $9.04 (≈$950.18K) on Sep 2, 2026
- Moatazedi David sold 105,108 shares at $9.04 (≈$950.18K) on Sep 2, 2026
- Moatazedi David sold 105,108 shares at $9.04 (≈$950.18K) on Sep 2, 2026
- Moatazedi David sold 105,108 shares at $9.04 (≈$950.18K) on Sep 2, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 2, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Aug 31, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 5, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Revenue: $84.08M (prior year $69.39M) (+21.2% vs Jun 30, 2025)
- Net income: -$8.05M (prior year -$17.14M) (loss narrowed vs Jun 30, 2025)
- Diluted EPS: -$0.12 (prior year -$0.27) (loss narrowed vs Jun 30, 2025)
Aug 5, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Aug 4, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 1.01 — Signed a material agreement.
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Jul 8, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 1.01 — Signed a material agreement.
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Things to know before you trade EOLS
- Last results release: Aug 5, 2026 (8-K Item 2.02). Previous ones: May 4, 2026, Mar 3, 2026, Jan 9, 2026. Based on that rhythm, the next report is likely around Nov 4, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 2.67% (largest 7.2%).
- Liquidity: about 724.53K shares (≈$5.14M) trade per day on average.
- 52-week position: $7.10 vs a range of $3.86–$9.31 (59% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 25 sales; latest: David Moatazedi sold 105,108 shares on Sep 2, 2026.
- Latest filings: 10-Q Aug 5, 2026; 8-K Aug 5, 2026; 8-K Aug 4, 2026.
- Share count: 66.05M shares outstanding (Jul 31, 2026), +2.1% vs a year earlier.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
EOLS market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 7.61 | 7.61 | 7.02 | 7.10 | 761.68K |
| Oct 15, 2026 | 7.26 | 7.71 | 7.22 | 7.57 | 901.50K |
| Oct 14, 2026 | 7.42 | 7.60 | 7.20 | 7.22 | 1.01M |
| Oct 13, 2026 | 7.68 | 7.70 | 7.48 | 7.51 | 654.40K |
| Oct 12, 2026 | 7.76 | 7.83 | 7.67 | 7.75 | 1.00M |
| Oct 9, 2026 | 7.77 | 7.83 | 7.61 | 7.73 | 430.10K |
| Oct 8, 2026 | 7.68 | 7.80 | 7.53 | 7.80 | 1.08M |
| Oct 7, 2026 | 7.37 | 7.75 | 7.33 | 7.74 | 595.10K |
| Oct 6, 2026 | 7.47 | 7.56 | 7.16 | 7.38 | 663.90K |
| Oct 5, 2026 | 7.07 | 7.52 | 7.07 | 7.47 | 786.40K |
| Oct 2, 2026 | 7.72 | 7.72 | 6.91 | 7.14 | 2.07M |
| Oct 1, 2026 | 7.89 | 8.01 | 7.69 | 7.69 | 922.60K |
| Sep 30, 2026 | 7.97 | 8.15 | 7.87 | 8.00 | 624.40K |
| Sep 29, 2026 | 7.91 | 8.11 | 7.83 | 7.99 | 415.10K |
| Sep 28, 2026 | 7.90 | 8.07 | 7.80 | 7.96 | 478.20K |
| Sep 25, 2026 | 7.84 | 8.00 | 7.71 | 7.97 | 398.30K |
| Sep 24, 2026 | 7.96 | 8.00 | 7.79 | 7.86 | 363.00K |
| Sep 23, 2026 | 8.33 | 8.51 | 7.88 | 8.00 | 415.90K |
| Sep 22, 2026 | 8.10 | 8.27 | 8.00 | 8.25 | 500.70K |
| Sep 21, 2026 | 7.93 | 7.99 | 7.76 | 7.99 | 420.70K |
About Evolus
Evolus (EOLS) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in NEWPORT BEACH, CA. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1570562.
EOLS board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| David N Gill | Director | Feb 19, 2026 |
| David Moatazedi | See Remarks | Sep 4, 2026 |
| Vikram Malik | Director | Feb 19, 2026 |
| Karah Herdman Parschauer | Director | Feb 19, 2026 |
| Brady Stewart | Director | Feb 19, 2026 |
| Albert G Iii White | Director | Feb 19, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Rui Avelar | See Remarks | Mar 20, 2026 |
| David Moatazedi | See Remarks | Sep 4, 2026 |
| Tatjana Mitchell | Chief Financial Officer | Feb 19, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Sep 2, 2026 | David Moatazedi | Sale | 105,108 | $9.04 |
| Sep 2, 2026 | David Moatazedi | Sale | 105,108 | $9.04 |
| Sep 2, 2026 | David Moatazedi | Sale | 105,108 | $9.04 |
| Sep 2, 2026 | David Moatazedi | Sale | 105,108 | $9.04 |
| Mar 20, 2026 | Rui Avelar | Sale | 3,119 | $4.75 |
| Mar 20, 2026 | Rui Avelar | Sale | 3,119 | $4.75 |
| Mar 20, 2026 | Rui Avelar | Sale | 3,119 | $4.75 |
| Mar 20, 2026 | Rui Avelar | Sale | 3,119 | $4.75 |
| Mar 20, 2026 | David Moatazedi | Sale | 13,669 | $4.75 |
| Mar 20, 2026 | David Moatazedi | Sale | 13,669 | $4.75 |
| Mar 20, 2026 | David Moatazedi | Sale | 13,669 | $4.75 |
| Mar 20, 2026 | David Moatazedi | Sale | 13,669 | $4.75 |
| Mar 17, 2026 | David Moatazedi | Sale | 116,720 | $4.89 |
| Mar 17, 2026 | David Moatazedi | Sale | 116,720 | $4.89 |
| Mar 17, 2026 | David Moatazedi | Sale | 116,720 | $4.89 |
EOLS financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $297.18M | $-51.64M | -0.80 | $-42.27M |
| Dec 31, 2024 | $266.27M | $-50.42M | -0.81 | $-18.00M |
| Dec 31, 2023 | $202.09M | $-61.69M | -1.08 | $-34.01M |
| Dec 31, 2022 | $148.62M | $-74.41M | -1.33 | $-84.91M |
| Dec 31, 2021 | $99.67M | $-46.81M | -0.94 | $-33.39M |
Latest balance sheet: total assets $248.02M, total liabilities $278.93M, cash $45.17M (as of Jun 30, 2026).
EOLS earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 5, 2026 | 8-K Item 2.02 (results) | $6.18 |
| May 4, 2026 | 8-K Item 2.02 (results) | $5.58 |
| Mar 3, 2026 | 8-K Item 2.02 (results) | $4.13 |
| Jan 9, 2026 | 8-K Item 2.02 (results) | $5.65 |
| Nov 5, 2025 | 8-K Item 2.02 (results) | $6.81 |
| Aug 5, 2025 | 8-K Item 2.02 (results) | $8.91 |
| May 7, 2025 | 8-K Item 2.02 (results) | $11.76 |
| Mar 4, 2025 | 8-K Item 2.02 (results) | $14.35 |
| Jan 21, 2025 | 8-K Item 2.02 (results) | $13.48 |
| Nov 6, 2024 | 8-K Item 2.02 (results) | $16.81 |
| Jul 31, 2024 | 8-K Item 2.02 (results) | — |
| May 7, 2024 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Novo Nordisk A S (NVO)Regeneron Pharmaceuticals (REGN)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on EOLS
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.